Lee is not concerned; his colleague Michael Jung, a medicinal chemist at U.C.L.A., had tinkered with
the original compound and found a series of variations that are 100-fold more potent.
Nguyen and Luu tackled this problem by tethering new biologically active appendages to the lab's
original compound, creating multitarget drugs that are small enough to get easily into cells.
Best of all, the derivatives were even more effective than
the original compound, without leading to that worrisome estrogenic metabolite or showing much affinity themselves for estrogen receptors.
To test the reaction's utility in drug discovery, Sharpless, Wu and their colleagues put 39 existing cancer drugs containing phenols into plates, added the liquid version of sulfuryl fluoride to each well, and exposed cancer cells to both
the original compounds and the resulting fluorosulfate versions.
Subsequently, derivatives with pharmacokinetic properties better than
the original compounds were synthesized.
Furthermore, the amazing studies on I3C date back further than DIM, since it was
the original compound to be discovered.
But if ingredients aren't mixed at the correct ratios, or aren't cooked properly,
the original compound may remain.
A large portion of these deaths occurred because most of the drug propoxyphene is converted into a metabolite that is highly toxic to the heart and lasts longer in the body than
the original compound.
Adding more lateral weight to the original adhesive is a bad idea if you don't know what
the original compound was, since different thinsets and mastics are designed for different shear weight.